5/8
08:07 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Mizuho from $109.00 to $106.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Mizuho from $109.00 to $106.00. They now have a "buy" rating on the stock.
5/8
07:08 am
axsm
Axsome Therapeutics to Present at Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics to Present at Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]
5/8
07:00 am
axsm
Axsome Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Axsome Therapeutics to Present at Upcoming Investor Conferences
5/7
01:27 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Citigroup Inc. from $127.00 to $125.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Citigroup Inc. from $127.00 to $125.00. They now have a "buy" rating on the stock.
5/7
01:10 pm
axsm
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates [Yahoo! Finance]
5/7
11:33 am
axsm
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/7
08:01 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
5/7
08:01 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $108.00 to $112.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $108.00 to $112.00. They now have an "outperform" rating on the stock.
5/6
01:08 pm
axsm
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/6
07:26 am
axsm
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/6
07:05 am
axsm
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Financial Post (Toronto, Ontario, Canada)]
5/6
07:00 am
axsm
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
5/1
07:13 am
axsm
Axsome Therapeutics Recognizes May as Mental Health Awareness Month [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Recognizes May as Mental Health Awareness Month [Financial Post (Toronto, Ontario, Canada)]
5/1
07:12 am
axsm
Axsome Therapeutics Recognizes May as Mental Health Awareness Month [Yahoo! Finance]
Low
Report
Axsome Therapeutics Recognizes May as Mental Health Awareness Month [Yahoo! Finance]
5/1
07:00 am
axsm
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Low
Report
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
4/30
09:00 pm
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/29
11:54 am
axsm
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/29
07:25 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $115.00 price target on the stock, up previously from $90.00.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $115.00 price target on the stock, up previously from $90.00.
4/22
09:34 am
axsm
15 Most Black States in the US [Yahoo! Finance]
Medium
Report
15 Most Black States in the US [Yahoo! Finance]
4/17
09:00 pm
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/15
07:10 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
4/15
07:09 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
4/15
07:00 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
4/12
02:30 am
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/10
10:19 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.